Being ultra conservative: <br /> <br /> Q1 $15M <br /> Q2 $26M <br /> Q3 $38M <br /> Q4 $50M <br /> <br /> Total 2012 Revenue of $129M. Company valued at 2X revenues would be $258M. If we have dilution to support the growth, i figure $2B issued. Based on these projections the real valued should be $.129 Regarding risk adjustment, I think there is a better chance of an upside buyout then a downside revenue projection. This stock will be a little undervalued for not being shareholder friendly. There is still a little lack of trust. So I think the stock goes above $.07 next week, and then continues to climb $.11 over the next three weeks. <br /> <br /> Once they blow away my projection of Q2, this stock will climb to $.15 <br /> <br /> If my Q1 revenue projections are too high or too low; I will need to adjust my numbers after the announcement. But MusclePharm is huge! And there is no slowing it down now. I complement management for the great growth. Let's hope they can be more friendly to us investors. They are moving in the right direction!